Oncogene-induced senescence: a double edged sword in cancer

Oncogene-induced cellular senescence (OIS) is a complex program that is triggered in response to aberrant activation of oncogenic signaling. Initially, OIS was thought to be a barrier to malignant transformation because of its suppression on cell proliferation. Later studies showed that senescence i...

Full description

Saved in:
Bibliographic Details
Published in:Acta pharmacologica Sinica 2018-10, Vol.39 (10), p.1553-1558
Main Authors: Liu, Xue-ling, Ding, Jian, Meng, Ling-hua
Format: Article
Language:English
Subjects:
Animals
Biomedical and Life Sciences
Biomedicine
Cancer
Cell proliferation
Cell Proliferation - physiology
Cell Transformation, Neoplastic - metabolism
Cellular Microenvironment - physiology
Cellular Senescence - genetics
Cellular Senescence - physiology
Humans
Immunology
Internal Medicine
Medical Microbiology
Molecular modelling
Neoplasms - etiology
Oncogenes
Oncogenes - genetics
Pharmacology/Toxicology
Review
Review Article
Senescence
Signal Transduction - physiology
Vaccine
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Oncogene-induced cellular senescence (OIS) is a complex program that is triggered in response to aberrant activation of oncogenic signaling. Initially, OIS was thought to be a barrier to malignant transformation because of its suppression on cell proliferation. Later studies showed that senescence induced by oncogenes can also promote the initiation and development of cancer. The opposing effects of OIS occur through different combinations of downstream effectors as well as the interplay of senescent cells and the microenvironment, such as senescence-associated inflammation. Here, we review the common features and molecular mechanisms underlying OIS and the interaction between senescent cells and the microenvironment. We propose that targeting senescent cells may have a beneficial therapeutic effect during the treatment of cancer.
ISSN:1671-4083
1745-7254
DOI:10.1038/aps.2017.198